Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tokai Raises $23 Million In Series D Financing

This article was originally published in The Pink Sheet Daily

Executive Summary

The start up's focus is on a highly competitive indication, refractory prostate cancer, but its ability to raise money could be tied to the novelty of its lead compound
Advertisement

Related Content

Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
Prostate Cancer Market Snapshot: More Than Provenge
Prostate Cancer Market Snapshot: More Than Provenge
Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK

Topics

Advertisement
UsernamePublicRestriction

Register

PS072802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel